H.C. Wainwright Reiterates Buy Rating on Grace Therapeutics (GRCE)

February 18, 2025 6:48 AM EST Send to a Friend
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating and $12.00 price target on Grace Therapeutics (NASDAQ: GRCE).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login